Mercury Laboratories Stock Screener | Share Price & Fundamental Analysis
MERCURYLAB
Pharmaceuticals
Share Price BSE
₹745.00
▼
-4.60 (-0.61%)
As of April 29, 2026, the Mercury Laboratories share price (BSE: MERCURYLAB) is ₹745.00, down 0.61% from the previous close, with shares trading between ₹731.25 and ₹770.00, and a 52-week range of ₹700.00–₹904.00.
Analyse MERCURYLAB price book multiple to evaluate book value versus market price.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Mercury Laboratories Market Cap
₹94.21 Cr.
MERCURYLAB P/E Ratio (TTM)
19.58
Mercury Laboratories P/B Ratio
1.66
EPS (TTM)
₹26.21
Dividend Yield
0.45%
Debt to Equity
0.11
MERCURYLAB 52 Week High
₹904.00
Mercury Laboratories 52 Week Low
₹700.00
Operating Margin
12.00%
Profit Margin
6.41%
MERCURYLAB Revenue (TTM)
₹78.00
EBITDA
₹10.00
Net Income
₹5.00
Total Assets
₹74.00
Total Equity
₹54.00
Mercury Laboratories Share Price History - Stock Screener Chart
Screen MERCURYLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Mercury Laboratories Company Profile - Fundamental Screener
Screen Mercury Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for MERCURYLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE947G01011
Mercury Laboratories Balance Sheet Screener
Screen MERCURYLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 74 | 68 | 64 | 62 | 65 | 56 | 57 | 52 | 51 | 47 |
| Current Assets | 40 | 40 | 40 | 35 | 38 | 32 | 32 | 30 | 32 | 28 |
| Fixed Assets | 25 | 24 | 24 | 26 | 26 | 24 | 24 | 21 | 18 | 19 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 6 | 5 | 4 | 6 | 10 | 9 | 11 | 12 | 10 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 54 | 51 | 46 | 40 | 37 | 32 | 29 | 26 | 25 | 22 |
| Share Capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves & Surplus | 52 | 50 | 44 | 39 | 36 | 31 | 28 | 25 | 23 | 21 |
Mercury Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Mercury Laboratories income statement and profit fundamentals.
Analyze MERCURYLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Mercury Laboratories share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 78 | 76 | 77 | 77 | 59 | 70 | 58 | 57 | 52 | 48 | 48 | 42 |
| Expenses | 67 | 68 | 67 | 67 | 51 | 59 | 51 | 50 | 48 | 41 | 41 | 35 |
| EBITDA | 10 | 8 | 10 | 10 | 8 | 11 | 7 | 7 | 5 | 7 | 7 | 7 |
| Operating Profit % | 12.00% | 9.00% | 12.00% | 11.00% | 12.00% | 14.00% | 11.00% | 10.00% | 9.00% | 14.00% | 14.00% | 14.00% |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Interest | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 6 | 5 | 7 | 7 | 5 | 8 | 4 | 4 | 3 | 5 | 5 | 5 |
| Tax | 2 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 0 | 2 | 1 | 1 |
| Net Profit | 5 | 3 | 6 | 6 | 4 | 5 | 3 | 3 | 2 | 3 | 4 | 3 |
| EPS | 39.30 | 26.21 | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 | 23.63 | 16.78 | 22.53 | 32.69 | 27.61 |
Mercury Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen MERCURYLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 4 | 8 | 3 | 5 | 8 | 6 | 5 | 5 | 2 | 0 |
| Investing Activities | -9 | -6 | -1 | -2 | -5 | -1 | -5 | -4 | -2 | 0 |
| Financing Activities | -1 | -1 | -1 | -1 | -1 | -3 | -3 | 1 | 0 | 1 |
| Net Cash Flow | -6 | 1 | 0 | 2 | 2 | 1 | -2 | 2 | 0 | 0 |
Mercury Laboratories Shareholding Pattern Screener
See Mercury Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Mercury Laboratories promoter holding and ownership changes for MERCURYLAB on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.58% | 16.66% | 16.66% | 16.71% | 16.59% | 16.86% | 16.86% | 16.79% |
| Other Holding | 9.77% | 9.68% | 9.68% | 9.63% | 9.76% | 9.48% | 9.48% | 9.55% |
| Shareholder Count | 1,316 | 1,397 | 1,384 | 1,365 | 1,321 | 1,214 | 1,259 | 1,345 |
Mercury Laboratories Share Dividend Screener - Share Yield Analysis
Check Mercury Laboratories dividend history with payout and yield data.
View Mercury Laboratories dividend details including ex-dates and amounts for MERCURYLAB stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹3.50 | 0.50% |
| 2024-March | ₹3.50 | 0.43% |
| 2023-March | ₹3.50 | 0.42% |
| 2022-March | ₹3.50 | 0.63% |
| 2021-March | ₹3.50 | 0.72% |
| 2020-March | ₹2.00 | 0.31% |
| 2019-March | ₹1.50 | 0.53% |
| 2018-March | ₹1.50 | 0.44% |
| 2017-March | ₹1.50 | 0.38% |
Mercury Laboratories Stock Index Membership
See which indices include Mercury Laboratories stock.
Check MERCURYLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Mercury Laboratories Market Events Screener - Corporate Actions
Get Mercury Laboratories corporate actions including splits, bonuses, and buybacks.
Check Mercury Laboratories stock events that may affect MERCURYLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 3.50 /share | 25.90% | ||
| Dividend | ₹ 2.00 /share | -10.51% | ||
| Dividend | ₹ 3.50 /share | 24.21% | ||
| Dividend | ₹ 3.50 /share | 19.51% | ||
| Annual General Meeting | NA | -1.49% | ||
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 2.06% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 2.38% |
| 2025-08-13 | 2025-08-13 | Annual General Meeting | NA | -4.77% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -6.45% |
| 2025-08-06 | 2025-08-06 | Dividend | ₹ 3.50 /share | -0.90% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -1.75% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -4.38% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.88% |
| 2021-02-22 | 2021-02-23 | Dividend | ₹ 1.50 /share | 4.00% |
Mercury Laboratories Competitors Screener - Peer Comparison
Screen MERCURYLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 419,236 | 37.98 | 54,729 | 9.71% | 10,980 | 55.87 |
| Divis Laboratories | 170,763 | 69.34 | 9,712 | 18.67% | 2,191 | 64.58 |
| Torrent Pharmaceuticals | 141,568 | 62.85 | 11,539 | 6.99% | 1,911 | 51.02 |
| Dr Reddys Laboratories | 113,061 | 20.17 | 33,741 | 16.73% | 5,725 | 66.78 |
| Cipla | 105,537 | 23.47 | 28,410 | 7.12% | 5,291 | 61.39 |
| Lupin | 105,243 | 22.76 | 22,910 | 13.74% | 3,306 | 49.06 |
| Mankind Pharma | 93,476 | 51.88 | 12,744 | 20.90% | 2,007 | 67.19 |
| Zydus Life Science | 91,698 | 18.66 | 23,511 | 18.55% | 4,615 | 48.96 |
| Aurobindo Pharma | 82,625 | 23.63 | 32,346 | 9.43% | 3,484 | 68.31 |
| Glenmark Pharmaceuticals | 67,833 | 61.60 | 13,436 | 6.18% | 1,047 | 71.16 |
Mercury Laboratories Company Announcements - News Screener
Screen MERCURYLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Results- Financial Results As On December 31 2025 | - |
| 2026-02-11 | Board Meeting Outcome for Outcome Of Board Meeting Held On 11.02.2026 | - |
| 2026-02-04 | Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2025 | - |
| 2026-01-03 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-11 | Updates On New Small Volume Parenteral (Svps) Plant At Jarod | - |
| 2025-11-11 | Unaudited Financial Results For The Quarter And Half Year Ended On September 2025 | - |
| 2025-11-11 | Board Meeting Outcome for Outcome Of Board Meeting Held On November 11 2025 | - |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-11-05 | Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended On September 30 2025 Scheduled To Be Held On November 11 2025 | - |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-10-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-10-04 | Communication To Shareholders Regarding 100 Days Campaign - Saksham Niveshak | - |
| 2025-09-25 | Closure of Trading Window | - |
| 2025-08-14 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |